| Bioactivity | Mephenytoin, an anticonvulsant, is the CYP2C19 and CYP2B6 substrate[1]. | ||||||||||||
| In Vivo | Mephenytoin (orally administration, 100 mg/kg, 200 mg/kg) can reduce maternal weight gain and increase offspring mortality at 200 mg/kg but not produce excessive offspring mortality at 100 mg/kg in Pregnant Sprague-Dawley CD rats[2].Mephenytoin (i.p., 20 mg/kg per day for 16 days) significantly reduces serum cholesterol and triglyceride levels in mice, which may have a hypolipidemic effect[3]. | ||||||||||||
| Name | Mephenytoin | ||||||||||||
| CAS | 50-12-4 | ||||||||||||
| Formula | C12H14N2O2 | ||||||||||||
| Molar Mass | 218.25 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Klaassen T, et al. Assessment of urinary mephenytoin metrics to phenotype for CYP2C19 and CYP2B6 activity. Eur J Clin Pharmacol. 2008;64(4):387-398. [2]. D R Minck, et al. Comparison of the behavioral teratogenic potential of phenytoin, mephenytoin, ethotoin, and hydantoin in rats. Teratology. 1991 Apr;43(4):279-93. [3]. J H Maguire, et al. Hypolipidemic activity of antiepileptic 5-phenylhydantoins in mice. Eur J Pharmacol. 1985 Oct 29;117(1):135-8. |